Daratumumab for delayed RBC engraftment following major ABO mismatched haploidentical bone marrow transplantation.

Abstract

BACKGROUND:

Recent case reports have described the efficacy of daratumumab to treat refractory pure red cell aplasia (PRCA) following major ABO mismatched allogeneic hematopoietic stem cell transplantation (HSCT). In this report, we describe the use of daratumumab as a first-line agent for treatment of delayed red blood cell (RBC) engraftment following a major ABO mismatched pediatric HSCT and provide a review of the literature.

STUDY DESIGN AND MATERIALS:

We report on a 14-year-old with DOCK8 deficiency who underwent a myeloablative, haploidentical bone marrow transplant from her major ABO mismatched sister (recipient O+, donor A+) for treatment of her primary immunodeficiency. Despite achieving full donor chimerism, she had delayed RBC engraftment requiring ongoing transfusions. Due to iron deposition, symptomatic anemia, and persistence of anti-A iso-hemagglutinins despite discontinuation of immunosuppression, treatment for delayed RBC engraftment with the CD38-targeted monoclonal antibody daratumumab was selected as a less immunosuppressive agent that could more selectively target iso-hemagglutinin producing plasma cells without causing broad B-cell aplasia.

RESULTS:

Clinical effect with daratumumab was demonstrated by reduced iso-hemagglutinin titer, increased reticulocytosis, normalization of her hemoglobin, and transfusion independence. In the 11-month follow-up period to date, no additional transfusions or immunosuppression have been necessary, despite persistence of low-level anti-A iso-hemagglutinin.

CONCLUSION:

Our experience suggests that daratumumab was an effective first-line therapy for delayed RBC engraftment and that earlier consideration for daratumumab in treatment of delayed RBC engraftment may be warranted.

• Authors: Bonnie Yates, Eoghan Molloy, Alina Dulau-Florea, Raul Braylan, Laura Hogan, Dennis D Hickstein, Alexandra F Freeman, Shelley S Kalsi, Nirali N Shah
• Journal: Transfusion (Transfusion) Vol. 61 Issue 4 Pg. 1041-1046 (04 2021) ISSN: 1537-2995 [Electronic] United States
• PMID: 33528026 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2021 AABB.

Chemical References

• ABO Blood-Group System
• Antibodies, Monoclonal
• DOCK8 protein, human
• Guanine Nucleotide Exchange Factors
• Hemagglutinins
• daratumumab

Topics

• ABO Blood-Group System (immunology)
• Adolescent
• Aftercare
• Antibodies, Monoclonal (administration & dosage, pharmacology, therapeutic use)
• Bone Marrow Transplantation (methods)
• Chimerism
• Delayed Graft Function (drug therapy)
• Erythrocytes (immunology)
• Female
• Guanine Nucleotide Exchange Factors (deficiency)
• Hemagglutinins (blood, drug effects)
• Humans
• Primary Immunodeficiency Diseases (diagnosis, genetics, therapy)
• Red-Cell Aplasia, Pure (drug therapy)
• Transplantation, Haploidentical (adverse effects)
• Treatment Outcome